Health-related quality of life after intensive care unit discharge: A comparison between 2 standard antibiotic regimens

M.A. Aldeyab, M.P. Kearney, M.G. Scott, J. Hanley, J.C. McElnay

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)807-808
Number of pages2
JournalInfection Control and Hospital Epidemiology
Issue number8
Publication statusPublished (in print/issue) - Aug 2009

Bibliographical note

Export Date: 15 September 2018


Correspondence Address: McElnay, J. C.; Department of Pharmacy Practice, Clinical and Practice Research Group, Queen's University Belfast, Belfast BT9 7BL, United Kingdom; email:

Chemicals/CAS: amoxicillin, 26787-78-0, 34642-77-8, 61336-70-7; ciprofloxacin, 85721-33-1; metronidazole, 39322-38-8, 443-48-1; Anti-Bacterial Agents; Ciprofloxacin, 85721-33-1; Penicillanic Acid, 87-53-6; Piperacillin, 61477-96-1; piperacillin-tazobactam combination product, 157044-21-8

Tradenames: tazocin

References: Kollef, M.H., Fraser, V.J., Antibiotic resistance in the intensive care unit (2001) Ann Intern Med, 134, pp. 298-314; Carlet, J., Ben Ali, A., Chalfine, A., Epidemiology and control of antibiotic resistance in the intensive care unit (2004) Curr Opin Infect Dis, 17, pp. 309-316; Mcgowan Jr., J.E., Antimicrobial resistance in hospital organisms and its relation to antibiotic use (1983) Rev Infect Dis, 5, pp. 1033-1048; Muller, A.A., Mauny, F., Bertin, M., Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital (2003) Clin Infect Dis, 36, pp. 971-978; Monnet, D.L., Mackenzie, F.M., Lopez-Lozano, J.M., Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000 (2004) Emerg Infect Dis, 10, pp. 1432-1441; Aldeyab, M.A., Monnet, D.L., López-Lozano, J.M., Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: A time-series analysis (2008) J Antimicrob Chemother, 62, pp. 593-600; Aldeyab, M.A., Hughes, C.M., Kearney, M.P., Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an intensive care unit (2008) Int J Antimicrob Agents, 32, pp. 499-504; EuroQol: A new facility for the measurement of health related quality of life (1990) Health Policy, 16, pp. 199-208. , EuroQol Group; Dolan, P., Modeling valuations for EuroQol health states (1997) Med Care, 35, pp. 1095-1108


  • amoxicillin
  • antibiotic agent
  • ciprofloxacin
  • metronidazole
  • piperacillin plus tazobactam
  • add on therapy
  • anaerobic infection
  • antibiotic resistance
  • antibiotic therapy
  • comparative study
  • health care
  • health care policy
  • health status
  • hospital discharge
  • human
  • intensive care unit
  • letter
  • methicillin resistant Staphylococcus aureus
  • methicillin resistant Staphylococcus aureus infection
  • nonhuman
  • quality of life
  • visual analog scale
  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Drug Resistance, Bacterial
  • Health Status
  • Humans
  • Intensive Care Units
  • Outcome Assessment (Health Care)
  • Patient Discharge
  • Penicillanic Acid
  • Piperacillin
  • Quality of Life
  • Questionnaires

Cite this